Members of the neurotrophin family and in particular brain-derived neurotrophic factor (BDNF) regulate the response to rapidand slow-acting chemical antidepressants and voluntary exercise. Recent work suggests that rapid-acting antidepressants that modulate N-methyl-D-aspartate receptor (NMDA-R) signaling (e.g., ketamine and GLYX-13) require expression of VGF (nonacronymic), the BDNF-inducible secreted neuronal protein and peptide precursor, for efficacy. In addition, the VGF-derived Cterminal peptide TLQP-62 (named by its 4 N-terminal amino acids and length) has antidepressant efficacy following icv or intrahippocampal administration, in the forced swim test (FST). Similar to ketamine, the rapid antidepressant actions of TLQP-62 require BDNF expression, mTOR activation (rapamycin-sensitive), and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor activation (NBQX-sensitive) and are associated with GluR1 insertion. We review recent findings that identify a rapidly induced autoregulatory feedback loop, which likely plays a critical role in sustained efficacy of rapid-acting antidepressants, depression-like behavior, and cognition, and requires VGF, its C-terminal peptide TLQP-62, BDNF/TrkB signaling, the mTOR pathway, and AMPA receptor activation and insertion.
Introduction
Brain-derived neurotrophic factor (BDNF) modulates depression-like behavior and antidepressant efficacy: decreased BDNF levels are found in depressed patients (Karege et al. 2005; Shimizu et al. 2003) , and BDNF infusion into the hippocampus or lateral ventricles produces antidepressant responses (Shirayama et al. 2002; Siuciak et al. 1997) . Thus, in the hippocampus, BDNF signaling modifies depressive behavior (Bjorkholm and Monteggia 2016; Jiang and Salton 2013) . In addition, a coding sequence variant (Val66Met) in the human BDNF gene is associated with cognitive and behavioral deficits and childhood-onset mood disorder (Egan et al. 2003; Strauss et al. 2005) . The functional impact of this BDNF polymorphism on depressive behavior and anxiety (Chen et al. 2006 ) and basic studies of BDNF sorting and release (Chen et al. 2005 (Chen et al. , 2004 demonstrate that altered trafficking and regulated secretion of BDNF drive behavioral outcomes. This and the association of ketamine's antidepressant efficacy with a subject's BDNF (Val/Met) genotype (Liu et al. 2012) suggest that local BDNF secretion regulates antidepressant responses.
BDNF regulates the expression of downstream genes, including robust induction of Vgf (non-acronymic, unrelated to VEGF), which encodes a neuropeptide precursor that is released via the regulated secretory pathway along with several VGF-derived peptides (reviewed in Levi et al. 2004; Salton et al. 2000) . Decreased VGF expression, resulting from germline or conditional Vgf gene ablation in mice, including targeted downregulation in adult dorsal hippocampus (dHc), impacts depressive behavior, contextual fear, and hippocampaldependent spatial memory (Bozdagi et al. 2008; Hahm et al. 1999; Hunsberger et al. 2007; Jiang et al. 2017; Lin et al. 2015) . VGF C-terminal peptides AQEE-30 and TLQP-62 (named by the four N-terminal amino acids and length) have antidepressant efficacy (Hunsberger et al. 2007; Jiang et al. 2017; Li et al. 2017; Lin et al. 2014; Thakker-Varia et al. 2007) , while TLQP-62 has also been shown to have procognitive efficacy Lin et al. 2015) . TLQP-62 functions via BDNF-dependent pathways (Bozdagi et al. 2008; Jiang et al. 2017; Lin et al. 2014 Lin et al. , 2015 , while the VGF 1-617 proprotein plays a critical role in growth factor, hormone, and neurotransmitter storage in dense core vesicles (DCVs) and regulated secretion (Fargali et al. 2014; Stephens et al. 2017) . Here, we review recent findings that suggest dual requirements for BDNF and VGF (TLQP-62), perhaps synthesized and secreted locally at the synapse, in the response to rapid-acting antidepressant drugs like ketamine.
Role of BDNF and Its Receptor TrkB in the Response to Rapid-Acting Antidepressants
BDNF, a member of the neurotrophin family, is widely synthesized in the CNS, in neurons and glia, where it regulates synaptic plasticity, and neuronal development and function (Park and Poo 2013; Parkhurst et al. 2013) . BDNF actions are transduced through the high-affinity tropomyosin receptor kinase B (TrkB) and through the low-affinity p75 neurotrophin receptor. The critical role that BDNF/TrkB signaling plays in MDD and the efficacy of rapid-acting antidepressants has been recognized through association studies of patients with BDNF single-nucleotide polymorphisms (SNPs) (Egan et al. 2003; Strauss et al. 2005 Strauss et al. , 2004 , and through investigation of depression-and anxiety-like behaviors in BDNF-deficient animal models and their response to antidepressants (reviewed in Bjorkholm and Monteggia 2016; Duman and Monteggia 2006; Jiang and Salton 2013; Krishnan and Nestler 2008) . The best-characterized BDNF SNP located in the proBDNF region changes the encoded valine to methionine (Val66Met), which alters BDNF sorting and reduces activity-dependent regulated secretion, resulting in impaired cognition and mood disorders (Chen et al. 2005 (Chen et al. , 2006 (Chen et al. , 2004 Egan et al. 2003) . Interestingly, knockin mouse models expressing variant human BDNF (Met66) have impaired working memory, increased anxiety-and depressionlike behavior, and reduced behavioral responses to conventional and rapid-acting antidepressants (Chen et al. 2006; Ghosal et al. 2018; Kato et al. 2017; Liu et al. 2012) . Thus, BDNF Met/Met mice have decreased responses to long-term fluoxetine treatment in the open field and novelty-induced hypophagia tests (Chen et al. 2006) , attenuated response to ketamine in the forced swim test (FST) (Liu et al. 2012) , no significant response to GLYX-13 in the FST, noveltysuppressed feeding test (NSFT), and female urine-sniffing test (Kato et al. 2017) , and lastly no significant responses to scopolamine in the FST or NSFT (Ghosal et al. 2018) .
The rapid antidepressant effects of the ionotropic glutamatergic N-methyl-D-aspartate (NMDA) receptor blocker ketamine were shown to require BDNF and pathways downstream of its high-affinity receptor TrkB and to require protein synthesis but not transcription, suggesting that BDNF may be locally translated in and secreted from dendrites (Autry et al. 2011; Lepack et al. 2016 Lepack et al. , 2014 Lepack et al. , 2015 . Similar to ketamine, the antidepressant actions of GLYX-13, a novel glutamatergic compound and NMDA modulator with glycine-like partial agonist properties (Kato et al. 2017) , and scopolamine, a nonselective muscarinic acetylcholine receptor antagonist (Ghosal et al. 2018) , may also mechanistically depend on rapid desuppression of translation of select mRNAs (e.g., BDNF). Importantly, the antidepressant efficacies of scopolamine and GLYX-13, like ketamine, are blocked by inhibitors of mammalian target of rapamycin (mTOR) (Li et al. 2010; Liu et al. 2017; Voleti et al. 2013 ) and require activation of eukaryotic elongation factor 2 kinase (eEF2K) (Autry et al. 2011; Nosyreva et al. 2013) . Local dendritic BDNF synthesis and secretion results at least in part from translation of the long 3′ untranslated region (UTR) BDNF mRNA isoform, which is transported to distal dendrites . Selective ablation of the long 3′UTR BDNF mRNA profoundly reduces activity-dependent BDNF secretion Lau et al. 2010) , impairs long-term potentiation (LTP) at dendritic synapses of hippocampal CA1 neurons ) and GABA-dependent neurogenesis , and results in hyperphagic obesity (Liao et al. 2012 (Liao et al. , 2015 . Whether the absence of the long 3′UTR BDNF mRNA also impacts depression-like behavior, antidepressant efficacy, and memory, as does the BDNF Val66Met SNP, remains to our knowledge unreported.
Contributions of the Secreted Protein and Peptide
Precursor VGF to the Response to Rapid-Acting Antidepressants VGF was originally cloned based on its induction by neurotrophins, including nerve growth factor (NGF), BDNF, and others (Alder et al. 2003; Bonni et al. 1995; Levi et al. 1985; Salton et al. 1991) , which stimulated investigation of its potential role in depression-like behavior and antidepressant efficacy. Interestingly, in the hippocampus, VGF was identified as one of the most robustly regulated mRNAs by prolonged voluntary exercise, a potent antidepressant in rodents (Hunsberger et al. 2007 ). Concurrently, VGF regulation by learned helplessness and the forced swim test (FST) was shown (Thakker-Varia et al. 2007 ). These studies further identified antidepressant efficacy of VGF-derived C-terminal peptides TLQP-62 (Thakker-Varia et al. 2007 ) and AQEE-30 (Hunsberger et al. 2007) , and a requirement for VGF expression in the antidepressant efficacy of exercise (Hunsberger et al. 2007 ). Subsequent reports have demonstrated a requirement for BDNF expression and BDNF/TrkB signaling in the antidepressant efficacy of TLQP-62 Li et al. 2017; Lin et al. 2014) . Prolonged antidepressant efficacy of TLQP-62, measured in the FST 3 and 6 days after a single intra-hippocampal infusion (Thakker-Varia et al. 2007 ), or in the FST and TST, measured after 2 weeks of daily intrahippocampal infusions (Lin et al. 2014) , could result at least in part from TLQP-62-mediated stimulation of hippocampal progenitor proliferation (Thakker-Varia et al. 2014 , 2007 . Rapid TLQP-62 antidepressant efficacy (30 min-24 h following intra-hippocampal delivery) in the FST Lin et al. 2014 ) has been shown, like the rapid-acting antidepressant ketamine, to require BDNF expression Lin et al. 2014) , mTOR activity (rapamycin-sensitive) , and glutamate receptor activity (NBQXsensitive) , suggesting a complementary, rapidly initiated mechanism of action. Lastly, recent studies have revealed a critical role for the VGF 1-617 proprotein in large dense core secretory vesicle (LDCV) biogenesis, in neuroendocrine adrenal medulla (Fargali et al. 2014) , and in pancreatic beta cells, where it is required for glucose-stimulated insulin secretion (Stephens et al. 2017) . Should VGF function similarly in the regulated secretory pathways of CNS neurons, altered VGF levels could also modulate activity-dependent BDNF release, and thus potentially depression-like behavior and antidepressant efficacy (Fig. 1) .
Are Rapid, Local Protein Synthesis and Secretion Critically Required for Antidepressant Efficacy?
As described above, pathways that regulate rapid, local protein synthesis, particularly those controlled by the mTOR pathway and eEF2K that control translational efficiency, have been implicated in the efficacy of rapid-acting antidepressants. However, simply increasing local synthesis of critical molecules at the synapse, including, for example, the neurotrophin BDNF and the AMPA receptor GluA1 subunit, is likely to be insufficient, as regulated secretion, protein sorting and processing, and/or posttranslational modification is also required for secretory and membrane proteins to be fully active and properly localized. Are structural components that could be required for local LDCV biogenesis also synthesized at the synapse? Dendritic RNAseq analysis of hippocampal neuropil with subsequent bioinformatic filtering has identified a number of mRNAs that encode granin proteins (e.g., Vgf, Scg2, Scg3, Scg5, ChgB) (Cajigas et al. 2012) , which are known to contribute to LDCV assembly, cargo sorting, and/or function (Bartolomucci et al. 2011) . A recent study further shows that BDNF/TrkB signaling regulates the dissociation of RNAbinding protein hnRNP K from specific mRNAs in hippocampal dendrites, including glutamate receptor mRNAs (e.g., GluA1, GluA2, and GluN1; Grik1, Grik2, Grik4, and Grik5; Gria1, Gria2, Gria3, and Gria4; Grin3a; Grm1, Grm2, Grm4, and Grm6; Grid1, Grid2); several mRNAs encoding proteins that function in the secretory pathway (e.g., Vgf, Scg2, Scg3, and Chga); and Bdnf, Ntrk2 (TrkB), and Ntrk3 mRNAs (Leal et al. 2017 ). In addition, BDNF/TrkB signaling has been reported to induce the dissembling of the RNA granular structure found in/under dendritic spines, a subcellular structure that is enriched for translational silencing/repressing factors, including DCP1, Ago2, and other P-body components (Cougot et al. 2008; Zeitelhofer et al. 2008 ). Loss of P-body-like granular RNA structure may be accompanied by trapped mRNA release as shown in previous studies in neurons and other cell types, allowing for local activation of mRNA translation (Buchan 2014) .
Growing evidence supports the existence of polyribosomes in dendritic spines with dynamic changes during associative fear learning (Jasinska et al. 2013; Ostroff et al. 2017) . Rough endoplasmic reticulum (RER) and trans-Golgi-like compartments have also been identified in dendrites (Pierce et al. 2001) , providing evidence for a satellite secretory pathway in spines. However, in general, mini-Golgi stacks or Golgi Boutposts^(GO) can be identified in only 20% of mature hippocampal neurons, tending to be more common in developing neurons and those that overexpress membrane proteins, while endoplasmic reticulum (ER) and ER-Golgi intermediate compartment (ERGIC) are found in all dendrites (Hanus and Ehlers 2016) . Locally assembled immature or mature secretory vesicles have not been shown to bud from GOs, although Golgi-independent secretion of GluA1 from dendrites can occur via non-canonical trafficking through recycling endosomes (Bowen et al. 2017 ). In addition, immature, coreglycosylated GluA2-containing glutamate receptors have been identified on neuronal membranes , suggesting that membrane receptors and/or secretory proteins, some locally synthesized, could be incompletely modified post-translationally and/or processed, but could still be inserted or released, and thus could have different functional properties and turnover rates compared to their mature forms.
In any case, despite incompletely understood pathways of dendritic membrane protein insertion and secretory protein processing and release, use of mTOR inhibitors (Li et al. 2010) or ablation of eukaryotic elongation factor 2 kinase (eEF2K) in knockout mice (Nosyreva et al. 2013) suggests that local translation is likely required for antidepressant efficacy. Ketamine has therefore been hypothesized to function by at least two independent, complementary mechanisms (Zanos and Gould 2018) including (1) via NMDA-R blockade that triggers a burst of glutamate release, AMPA-R activation, BDNF release and TrkB activation, and an mTOR-mediated increase in local protein synthesis (Abdallah et al. 2015; Li et al. 2010) , or (2) via suppression of spontaneous NMDA-Rmediated neurotransmission, which potentiates synaptic responses in hippocampal CA1, inhibits eEF2K activity, and desuppresses BDNF translation (Autry et al. 2011; Bjorkholm and Monteggia 2016; Miller et al. 2014; Nosyreva et al. 2013 ).
Function of the VGF/BDNF/TrkB Autoregulatory Feedback Loop in Plasticity Associated with Depression-Like Behavior and Memory
Localized changes in synaptic plasticity that increase the activity of specific synapses and neural circuits occur in response to administration of rapid-acting antidepressants, including ketamine (Lepack et al. 2016 (Lepack et al. , 2014 (Lepack et al. , 2015 , GLYX-13 (Kato et al. 2017; Liu et al. 2017) , scopolamine (Ghosal et al. 2018) , and the VGF peptide TLQP-62 Li et al. 2017; Lin et al. 2014) . It has been proposed that these changes are regulated by local translation and activity-dependent release of BDNF (Leal et al. 2013; Santos et al. 2010; Waterhouse and Xu 2009) and by VGF and VGF-derived C-terminal neuropeptides (Jiang et al. 2017) (Fig. 1) . These recent studies suggest a model whereby paracrine and/or autocrine BDNF secretion, triggered by neuronal activity, including by a proposed glutamate surge in response to NMDA-R or M1-acetylcholine-R antagonism, increases BDNF/TrkB signaling in a selfreinforcing autoregulatory loop that could be required for the sustained efficacy of rapid-acting antidepressants. In addition to activity-dependent BDNF release, increased local translation of BDNF and possibly VGF, via increased mTOR activity and/or decreased eEF2K activity that leads to rapid desuppression of translation, would result in further BDNF, VGF, and TLQP-62 secretion. BDNF via TrkB activation could then increase mTOR pathway activity and decrease eEF2K activity, resulting in increased AMPA receptor insertion (containing GluA1 and GluA2 subunits), and plasticity-related changes that lead to prolonged antidepressant effects, which can last for days or weeks. Fig. 1 A VGF/BDNF/TrkB autoregulatory feedback loop stimulates synaptic plasticity changes in response to rapid-acting antidepressant treatment. This diagram summarizes the dendritic signaling pathways (left side) and subcellular compartments (right side) that have been suggested to contribute to rapid antidepressant responses. Ketamine and scopolamine by stimulating a surge of glutamate release, GLYX-13 via NMDA-R modulation, and TLQP-62 via a yet to be identified receptor trigger BDNF release, increase BDNF/TrkB signaling, regulate dissociation of RNA binding protein hnRNP K from specific mRNAs, and desuppress translation via mTOR and/or eEF2 pathways. Thus, rapid local synthesis and insertion of GluR1, and rapid local synthesis and secretion of VGF (TLQP-62) and BDNF, are increased, stimulating synaptic plasticity. Identified subcellular compartments in dendrites through which receptors for insertion and proteins for secretion are trafficked include the endoplasmic reticulum-Golgi intermediate compartment (ERGIC) . Vesicles budding from ERGIC that incorporate receptors with immature patterns of core glycosylation have been identified as endosomes. Large dense core secretory vesicles of the regulated secretory pathway, which could support protein processing (e.g., proBDNF to BDNF) remain to be identified. LDCV, large dense core vesicle; Rapa, rapamycin; VDCC, voltage-dependent calcium channel
